| Management of cardiogenic shock due to acute coronary syndromes. | |
| | |
MedLine Citation:
|
PMID: 15793600 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Despite advances in the treatment of patients with acute coronary syndromes, there has been no significant decrease in the incidence of cardiogenic shock, while its mortality remains frustratingly high. Shock is a progressive state of hypotension (systolic blood pressure < 90 mm Hg) lasting at least 30 minutes, which leads to systemic hypoperfusion. It is more common in patients with ST-segment elevation myocardial infarction than in patients with other acute coronary syndromes. Revascularization is associated with better outcomes than intensive medical therapy, especially in patients < 75 years of age with cardiogenic shock. Adjunctive therapies include inotropes, vasopressor therapy, intra-aortic balloon pump counterpulsation, and IIb/IIIa blockade to prevent no-reflow phenomenon during primary percutaneous transluminal coronary angioplasty. Other adjunctive therapies which are investigated are improved mechanical support devices, and as medical therapy for myocyte protection nicorandil, glucose/insulin/potassium infusions and direct inhibition of Na+/H+ exchanger. |
| | |
Authors:
|
Konstantina P Bouki; Georgios Pavlakis; Evaggelos Papasteriadis |
Publication Detail:
|
Type: Comparative Study; Journal Article; Review |
Journal Detail:
|
Title: Angiology Volume: 56 ISSN: 0003-3197 ISO Abbreviation: Angiology Publication Date: 2005 Mar-Apr |
Date Detail:
|
Created Date: 2005-03-28 Completed Date: 2005-05-24 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0203706 Medline TA: Angiology Country: United States |
Other Details:
|
Languages: eng Pagination: 123-30 Citation Subset: IM |
Affiliation:
|
1st Department of Cardiology, General Hospital of Nikea, Pireaus, Greece. epapak@tee.gr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cardiotonic Agents
/
therapeutic use Coronary Disease / complications*, mortality, therapy Humans Intra-Aortic Balloon Pumping Myocardial Revascularization Platelet Aggregation Inhibitors / therapeutic use Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors Shock, Cardiogenic / etiology, mortality, therapy* Survival Rate Syndrome Treatment Outcome Vasoconstrictor Agents / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Cardiotonic Agents; 0/Platelet Aggregation Inhibitors; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 0/Vasoconstrictor Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons.
Next Document: Right bundle branch block in acute myocardial infarction treated by primary coronary angioplasty and...